FDA Approves Polatuzumab Vedotin-Piiq Combination for DLBCL Patients

Leggi l'articolo originale


The FDA granted accelerated approval to polatuzumab vedotin-piiq, a CD79b-directed antibody-drug conjugate, in combination with bendamustine and a rituximab product for adult patients with relapsed or refractory diffuse large B-cell lymphoma.

Lascia un commento